Modulation of DNA methylation by a sesquiterpene lactone parthenolide

Zhongfa Liu, Shujun Liu, Zhiliang Xie, Ryan E. Pavlovicz, Jiejun Wu, Ping Chen, Josephine Aimiuwu, Jiuxia Pang, Deepak Bhasin, Paolo Neviani, James R. Fuchs, Christoph Plass, Pui Kai Li, Chenglong Li, Hui-ming Huang, Lai Chu Wu, Laura Rush, Hongyan Wang, Danilo Perrotti, Guido Marcucci & 1 others Kenneth K. Chan

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Hypermethylation of 5′-cytosine-guanosine islands of tumor suppressor genes resulting in their silencing has been proposed to be a hallmark of various tumors. Modulation of DNA methylation with DNA methylation inhibitors has been shown to result in cancer cell differentiation or apoptosis and represents a novel strategy for chemotherapy. Currently, effective DNA methylation inhibitors are mainly limited to decitabine and 5-azacytidine, which still show unfavorable toxicity profiles in the clinical setting. Thus, discovery and development of novel hypomethylating agents, with a more favorable toxicity profile, is essential to broaden the spectrum of epigenetic therapy. Parthenolide, the principal bioactive sesquiterpene lactone of feverfew, has been shown to alkylate Cys 38 of p65 to inhibit nuclear factor-κB activation and exhibit anti-tumor activity in human malignancies. In this article, we report that parthenolide 1) inhibits DNA methyltransferase 1 (DNMT1) with an IC 50 of 3.5 μM, possibly through alkylation of the proximal thiolate of Cys 1226 of the catalytic domain by its γ-methylene lactone, and 2) down-regulates DNMTI expression possibly associated with its SubG., cell-cycle arrest or the interruption of transcriptional factor Sp1 binding to the promoter of DNMTI. These dual functions of parthenolide result in the observed in vitro and in vivo global DNA hypomethylation. Furthermore, parthenolide has been shown to reactivate tumor suppressor HIN-1 gene in vitro possibly associated with its promoter hypomethylation. Hence, our study established parthenolide as an effective DNA methylation inhibitor, representing a novel prototype for DNMT1 inhibitor discovery and development from natural structural-diversified sesquiterpene lactones.

Original languageEnglish (US)
Pages (from-to)505-514
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume329
Issue number2
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Sesquiterpenes
Lactones
DNA Methylation
decitabine
Methyltransferases
Neoplasms
DNA
Tanacetum parthenium
Azacitidine
Guanosine
Cytosine
Alkylation
Cell Cycle Checkpoints
Tumor Suppressor Genes
Islands
Epigenomics
Human Activities
Cell Differentiation
Catalytic Domain
Down-Regulation

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Medicine(all)

Cite this

Liu, Z., Liu, S., Xie, Z., Pavlovicz, R. E., Wu, J., Chen, P., ... Chan, K. K. (2009). Modulation of DNA methylation by a sesquiterpene lactone parthenolide. Journal of Pharmacology and Experimental Therapeutics, 329(2), 505-514. https://doi.org/10.1124/jpet.108.147934

Modulation of DNA methylation by a sesquiterpene lactone parthenolide. / Liu, Zhongfa; Liu, Shujun; Xie, Zhiliang; Pavlovicz, Ryan E.; Wu, Jiejun; Chen, Ping; Aimiuwu, Josephine; Pang, Jiuxia; Bhasin, Deepak; Neviani, Paolo; Fuchs, James R.; Plass, Christoph; Li, Pui Kai; Li, Chenglong; Huang, Hui-ming; Wu, Lai Chu; Rush, Laura; Wang, Hongyan; Perrotti, Danilo; Marcucci, Guido; Chan, Kenneth K.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 329, No. 2, 05.2009, p. 505-514.

Research output: Contribution to journalArticle

Liu, Z, Liu, S, Xie, Z, Pavlovicz, RE, Wu, J, Chen, P, Aimiuwu, J, Pang, J, Bhasin, D, Neviani, P, Fuchs, JR, Plass, C, Li, PK, Li, C, Huang, H, Wu, LC, Rush, L, Wang, H, Perrotti, D, Marcucci, G & Chan, KK 2009, 'Modulation of DNA methylation by a sesquiterpene lactone parthenolide', Journal of Pharmacology and Experimental Therapeutics, vol. 329, no. 2, pp. 505-514. https://doi.org/10.1124/jpet.108.147934
Liu, Zhongfa ; Liu, Shujun ; Xie, Zhiliang ; Pavlovicz, Ryan E. ; Wu, Jiejun ; Chen, Ping ; Aimiuwu, Josephine ; Pang, Jiuxia ; Bhasin, Deepak ; Neviani, Paolo ; Fuchs, James R. ; Plass, Christoph ; Li, Pui Kai ; Li, Chenglong ; Huang, Hui-ming ; Wu, Lai Chu ; Rush, Laura ; Wang, Hongyan ; Perrotti, Danilo ; Marcucci, Guido ; Chan, Kenneth K. / Modulation of DNA methylation by a sesquiterpene lactone parthenolide. In: Journal of Pharmacology and Experimental Therapeutics. 2009 ; Vol. 329, No. 2. pp. 505-514.
@article{4832e083663f4af684b92f737e5eaf6f,
title = "Modulation of DNA methylation by a sesquiterpene lactone parthenolide",
abstract = "Hypermethylation of 5′-cytosine-guanosine islands of tumor suppressor genes resulting in their silencing has been proposed to be a hallmark of various tumors. Modulation of DNA methylation with DNA methylation inhibitors has been shown to result in cancer cell differentiation or apoptosis and represents a novel strategy for chemotherapy. Currently, effective DNA methylation inhibitors are mainly limited to decitabine and 5-azacytidine, which still show unfavorable toxicity profiles in the clinical setting. Thus, discovery and development of novel hypomethylating agents, with a more favorable toxicity profile, is essential to broaden the spectrum of epigenetic therapy. Parthenolide, the principal bioactive sesquiterpene lactone of feverfew, has been shown to alkylate Cys 38 of p65 to inhibit nuclear factor-κB activation and exhibit anti-tumor activity in human malignancies. In this article, we report that parthenolide 1) inhibits DNA methyltransferase 1 (DNMT1) with an IC 50 of 3.5 μM, possibly through alkylation of the proximal thiolate of Cys 1226 of the catalytic domain by its γ-methylene lactone, and 2) down-regulates DNMTI expression possibly associated with its SubG., cell-cycle arrest or the interruption of transcriptional factor Sp1 binding to the promoter of DNMTI. These dual functions of parthenolide result in the observed in vitro and in vivo global DNA hypomethylation. Furthermore, parthenolide has been shown to reactivate tumor suppressor HIN-1 gene in vitro possibly associated with its promoter hypomethylation. Hence, our study established parthenolide as an effective DNA methylation inhibitor, representing a novel prototype for DNMT1 inhibitor discovery and development from natural structural-diversified sesquiterpene lactones.",
author = "Zhongfa Liu and Shujun Liu and Zhiliang Xie and Pavlovicz, {Ryan E.} and Jiejun Wu and Ping Chen and Josephine Aimiuwu and Jiuxia Pang and Deepak Bhasin and Paolo Neviani and Fuchs, {James R.} and Christoph Plass and Li, {Pui Kai} and Chenglong Li and Hui-ming Huang and Wu, {Lai Chu} and Laura Rush and Hongyan Wang and Danilo Perrotti and Guido Marcucci and Chan, {Kenneth K.}",
year = "2009",
month = "5",
doi = "10.1124/jpet.108.147934",
language = "English (US)",
volume = "329",
pages = "505--514",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Modulation of DNA methylation by a sesquiterpene lactone parthenolide

AU - Liu, Zhongfa

AU - Liu, Shujun

AU - Xie, Zhiliang

AU - Pavlovicz, Ryan E.

AU - Wu, Jiejun

AU - Chen, Ping

AU - Aimiuwu, Josephine

AU - Pang, Jiuxia

AU - Bhasin, Deepak

AU - Neviani, Paolo

AU - Fuchs, James R.

AU - Plass, Christoph

AU - Li, Pui Kai

AU - Li, Chenglong

AU - Huang, Hui-ming

AU - Wu, Lai Chu

AU - Rush, Laura

AU - Wang, Hongyan

AU - Perrotti, Danilo

AU - Marcucci, Guido

AU - Chan, Kenneth K.

PY - 2009/5

Y1 - 2009/5

N2 - Hypermethylation of 5′-cytosine-guanosine islands of tumor suppressor genes resulting in their silencing has been proposed to be a hallmark of various tumors. Modulation of DNA methylation with DNA methylation inhibitors has been shown to result in cancer cell differentiation or apoptosis and represents a novel strategy for chemotherapy. Currently, effective DNA methylation inhibitors are mainly limited to decitabine and 5-azacytidine, which still show unfavorable toxicity profiles in the clinical setting. Thus, discovery and development of novel hypomethylating agents, with a more favorable toxicity profile, is essential to broaden the spectrum of epigenetic therapy. Parthenolide, the principal bioactive sesquiterpene lactone of feverfew, has been shown to alkylate Cys 38 of p65 to inhibit nuclear factor-κB activation and exhibit anti-tumor activity in human malignancies. In this article, we report that parthenolide 1) inhibits DNA methyltransferase 1 (DNMT1) with an IC 50 of 3.5 μM, possibly through alkylation of the proximal thiolate of Cys 1226 of the catalytic domain by its γ-methylene lactone, and 2) down-regulates DNMTI expression possibly associated with its SubG., cell-cycle arrest or the interruption of transcriptional factor Sp1 binding to the promoter of DNMTI. These dual functions of parthenolide result in the observed in vitro and in vivo global DNA hypomethylation. Furthermore, parthenolide has been shown to reactivate tumor suppressor HIN-1 gene in vitro possibly associated with its promoter hypomethylation. Hence, our study established parthenolide as an effective DNA methylation inhibitor, representing a novel prototype for DNMT1 inhibitor discovery and development from natural structural-diversified sesquiterpene lactones.

AB - Hypermethylation of 5′-cytosine-guanosine islands of tumor suppressor genes resulting in their silencing has been proposed to be a hallmark of various tumors. Modulation of DNA methylation with DNA methylation inhibitors has been shown to result in cancer cell differentiation or apoptosis and represents a novel strategy for chemotherapy. Currently, effective DNA methylation inhibitors are mainly limited to decitabine and 5-azacytidine, which still show unfavorable toxicity profiles in the clinical setting. Thus, discovery and development of novel hypomethylating agents, with a more favorable toxicity profile, is essential to broaden the spectrum of epigenetic therapy. Parthenolide, the principal bioactive sesquiterpene lactone of feverfew, has been shown to alkylate Cys 38 of p65 to inhibit nuclear factor-κB activation and exhibit anti-tumor activity in human malignancies. In this article, we report that parthenolide 1) inhibits DNA methyltransferase 1 (DNMT1) with an IC 50 of 3.5 μM, possibly through alkylation of the proximal thiolate of Cys 1226 of the catalytic domain by its γ-methylene lactone, and 2) down-regulates DNMTI expression possibly associated with its SubG., cell-cycle arrest or the interruption of transcriptional factor Sp1 binding to the promoter of DNMTI. These dual functions of parthenolide result in the observed in vitro and in vivo global DNA hypomethylation. Furthermore, parthenolide has been shown to reactivate tumor suppressor HIN-1 gene in vitro possibly associated with its promoter hypomethylation. Hence, our study established parthenolide as an effective DNA methylation inhibitor, representing a novel prototype for DNMT1 inhibitor discovery and development from natural structural-diversified sesquiterpene lactones.

UR - http://www.scopus.com/inward/record.url?scp=65649091667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649091667&partnerID=8YFLogxK

U2 - 10.1124/jpet.108.147934

DO - 10.1124/jpet.108.147934

M3 - Article

VL - 329

SP - 505

EP - 514

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -